Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity
Laura Valenzuela‐Vallejo, Pavlina Chrysafi, Jenny C. Bello-Ramos, Shahd Bsata, Christos S. Mantzoros
Topics & Concepts
LiraglutideInternal medicineEndocrinologyAgonistPlaceboWeight lossMedicineType 2 diabetesObesityReceptorDiabetes mellitusAlternative medicinePathologyGDF15 and Related BiomarkersIL-33, ST2, and ILC PathwaysAdipokines, Inflammation, and Metabolic Diseases